Where to Get a Full Body Scan and What It Costs

Full body scans are available at private screening centers, concierge health clinics, and some academic medical centers, with prices typically ranging from around $500 for a basic CT scan up to $2,500 or more for a whole-body MRI. The market for these scans has grown rapidly, driven by direct-to-consumer companies and a wave of interest in preventive health. But pricing, scan quality, and what happens after you get results vary enormously depending on where you go and which imaging technology is used.

Types of Full Body Scans and How They Differ

The term “full body scan” covers several different imaging technologies, and the differences between them matter for both your wallet and your health. The three main options are whole-body CT, whole-body MRI, and PET/CT, each with distinct strengths and trade-offs.

Whole-body CT uses X-rays to produce detailed cross-sectional images of the body. It is fast, widely available, and especially good at spotting lung nodules and calcified structures. However, it involves ionizing radiation, which carries a small but real cumulative cancer risk over time. A modeling study found that for a 40-year-old man, a single PET/CT scan carried a lifetime attributable cancer risk of about 0.17%, and that risk climbed to roughly 0.85% with annual scans over five years.¹ Standard whole-body CT involves less radiation than PET/CT, but the cumulative concern remains for people who plan to scan repeatedly.

Whole-body MRI uses magnetic fields instead of radiation, which eliminates the ionizing-radiation risk entirely. A core MRI protocol can cover the entire body in under 40 minutes and can be extended with additional sequences for specific regions as needed.² MRI tends to be more specific than CT, meaning it is better at distinguishing harmless tissue from something suspicious, though CT remains superior for detecting very small lung nodules.³ Modern whole-body MRI protocols now integrate functional imaging techniques that can help characterize abnormalities beyond their shape and size.⁴

PET/CT combines a CT scan with a radioactive tracer that highlights metabolically active tissue, which is useful for cancer staging and monitoring. It is the most expensive option and involves the most radiation. PET/CT is rarely used for general screening in healthy people; it is primarily a clinical tool for patients who already have a known or strongly suspected cancer.

Where You Can Actually Get One

A decade ago, finding a place to get a preventive full body scan meant seeking out a handful of entrepreneurial radiology clinics. Today the landscape is much broader, and your options generally fall into a few categories.

Direct-to-consumer screening companies are the fastest-growing segment. Companies such as Prenuvo, Ezra, and SimonMed operate scanning centers in major metropolitan areas and market whole-body MRI scans directly to consumers without requiring a doctor’s referral. These companies have raised the public profile of full body scanning considerably. Their facilities are typically located in larger cities, so access is limited if you live in a rural area. Appointment wait times at popular locations can stretch weeks or months.

Independent imaging centers and radiology practices in many cities offer whole-body CT or MRI scans on a cash-pay basis. These are often less expensive than branded screening companies, though the experience varies widely. Some provide detailed post-scan consultations with a radiologist, while others hand you a report and suggest you follow up with your own doctor.

Academic medical centers and large hospital systems sometimes offer whole-body MRI as part of executive health programs or preventive screening packages. These tend to be more expensive, but you get the benefit of radiologists who read these scans routinely in a clinical context, and the results are more easily integrated into your medical record. A radiologist-led screening program typically includes structured management of any findings, with clear pathways for follow-up imaging or specialist referral.⁵

Concierge and longevity medicine practices frequently bundle full body scans into comprehensive annual health assessments alongside blood panels, cardiac stress tests, and other evaluations. These packages can cost $5,000 to $20,000 or more, with the scan itself being just one component.

What It Costs

Prices for full body scans vary by technology, location, and provider. Here are the general ranges you can expect as of 2024-2025:

Whole-body CT: Typically $500 to $1,500 at private screening centers. This is the least expensive option, partly because CT scanners are widely available and scans take only a few minutes.
Whole-body MRI: Generally $1,500 to $3,000 at direct-to-consumer companies, though some providers charge less and executive health programs may charge more. Prenuvo, one of the better-known companies, prices its full body scan at around $2,500 in most markets.
PET/CT: Ranges from $3,000 to $6,000 or more. Because PET/CT involves a radioactive tracer and specialized equipment, it is inherently more expensive and almost always requires a medical indication.

Insurance almost never covers full body scans performed for general screening in healthy people. These scans are considered elective, and no major medical society currently recommends routine full body scanning for the general population. If your doctor orders a scan because of a specific clinical concern, such as staging a known cancer or investigating unexplained symptoms, insurance will typically cover it. But the cash-pay screening market operates outside that framework entirely. Some screening companies offer financing plans or payment installments.

What Full Body Scans Actually Find

One of the most striking things about full body scans is just how much they find, most of which turns out to be harmless. Across major screening cohorts, somewhere between 78% and 97% of people who undergo whole-body MRI have at least one reportable finding, with roughly 10% to 25% of those findings classified as clinically significant or warranting further evaluation.⁵ The most common actionable discoveries include kidney cysts or solid kidney masses, liver lesions, ovarian cysts, thyroid nodules, and adrenal growths.

A systematic review of preventive whole-body MRI screening found that about a third of screened individuals had either a critical or indeterminate incidental finding. When the studies included cardiovascular or colon imaging in the protocol, that figure climbed to about half of all participants.⁶ Critical findings alone, meaning things that clearly needed medical attention, showed up in roughly one in eight people screened.

When it comes to actual cancer, the detection rate is much lower. A meta-analysis of over 9,000 asymptomatic individuals who underwent whole-body MRI found a confirmed cancer rate of about 1.6%.⁷ That means for every hundred people scanned, roughly one or two had a cancer detected. Whether catching those cancers early enough to change outcomes is still an open question, since no large randomized trial has yet demonstrated that whole-body screening in the general population reduces cancer deaths.

The Incidental Finding Problem

The high detection rate of “something” is both the appeal and the headache of full body scanning. Most of what shows up is benign: a cyst here, a small nodule there, a benign growth that would never have caused symptoms. But once something is seen on a scan, it often triggers a cascade of follow-up tests, specialist referrals, and sometimes biopsies to confirm it is truly harmless.

A cost-effectiveness analysis of whole-body CT screening illustrated this clearly. In the model, over 90% of screened patients had at least one positive finding, but only about 2% actually had disease. The workups for people with false-positive results accounted for roughly a third of total screening costs.⁸ So even setting aside the price of the scan itself, the downstream expenses from chasing down benign findings add up quickly.

Research on incidental findings in whole-body MRI of prostate cancer patients found that about 8% of all incidental findings were clinically significant, and the rate was notably higher in patients over 75 compared to younger ones.⁹ This makes intuitive sense: older bodies accumulate more benign abnormalities, so the ratio of “things that look suspicious” to “things that are actually dangerous” shifts with age.

The psychological dimension matters too. Getting a scan that reveals several “findings” can generate significant anxiety, even when follow-up confirms everything is fine. And the follow-up process itself can take weeks or months, during which you may be worrying about something that turns out to be a cyst your body has been carrying harmlessly for years.

Who Benefits Most

The evidence for full body scanning is much stronger for people with known risk factors than for the general population walking in off the street. Whole-body MRI has an established role in monitoring certain hereditary cancer syndromes, staging known cancers, and screening people at very high genetic risk.

The clearest example is Li-Fraumeni syndrome, a rare genetic condition caused by mutations in the TP53 gene that dramatically increases lifetime cancer risk. In asymptomatic carriers who underwent baseline whole-body MRI, about 31% had suspicious lesions detected, and roughly 6% were ultimately diagnosed with cancer, the vast majority at an early stage.¹⁰ A 6% cancer detection rate in an asymptomatic group is exceptionally high compared to the roughly 1.6% rate seen in the general screening population. For these patients, regular whole-body MRI is widely recommended by clinical guidelines and genuinely saves lives.

More broadly, whole-body MRI has growing support as a complement to standard screening tests for people at elevated risk. Because it covers organs not targeted by conventional screening programs like mammography or colonoscopy, it can pick up cancers in locations that would otherwise go unmonitored.¹¹ That said, “elevated risk” is a clinical judgment, not a marketing category. Having a first-degree relative with cancer, carrying a known genetic variant, or having a personal history of cancer all qualify. Being generally anxious about your health does not put you in a high-risk category where the scan’s benefits clearly outweigh the false-positive costs.

The Cost-Effectiveness Question

For the average healthy person, the math on full body scanning is not favorable. The cost-effectiveness analysis of whole-body CT screening found that it added an average of just six days to life expectancy compared to routine care, at an additional cost of about $2,500 per patient. The incremental cost came out to roughly $151,000 per life-year gained, which is well above the thresholds that health economists typically consider good value.⁸

That study modeled CT, not MRI, and the economics of MRI screening may look different because MRI avoids radiation and has better specificity, potentially reducing some of the false-positive burden. But no published cost-effectiveness analysis has yet demonstrated that whole-body MRI screening in the general population meets conventional value benchmarks either. The fundamental challenge remains: when you scan thousands of healthy people, you find many things, most of them benign, and the cost of investigating all those findings is steep relative to the small number of genuine diseases caught early enough to change the outcome.

This is not the same as saying the scans are worthless. For someone who has the disposable income and wants the peace of mind, or who falls into a gray zone of risk that does not quite trigger formal screening guidelines, a full body scan could catch something early. The issue is that at a population level, the numbers do not support recommending it for everyone.

Questions Worth Asking Before You Book

If you are considering a full body scan, a few practical questions can help you evaluate the offering and avoid common pitfalls:

CT or MRI? If you are paying out of pocket for a general screening scan and do not have a specific clinical indication, whole-body MRI is the stronger choice because it avoids radiation entirely. CT’s edge in detecting tiny lung nodules matters more in clinical contexts than in general screening.
Who reads the scan? The quality of the radiologist interpreting your images matters as much as the scanner itself. Experience with whole-body protocols is specialized, and readers with less experience may miss subtle findings or over-call benign ones. Research comparing experienced and less experienced readers found meaningful differences in sensitivity and specificity.³
What happens after? Ask whether the service includes a consultation to explain your results, and whether they have a structured pathway for managing findings that need follow-up. A scan that generates a 15-page report full of medical terminology and leaves you to figure it out on your own is not a complete service.
What is your baseline risk? If you have a strong family history of cancer, a known genetic syndrome, or a personal cancer history, the scan is more likely to find something meaningful and the case for screening is stronger. If you are a healthy 30-year-old with no risk factors, the probability of finding actionable disease is very low, while the probability of finding something benign that triggers expensive and anxiety-inducing follow-up is high.

MRI Versus CT for Screening Specifically

Because many consumers face the choice between a cheaper CT scan and a pricier MRI, it is worth understanding why radiologists increasingly favor MRI for screening healthy people. Beyond the radiation issue, MRI’s higher specificity is a real practical advantage. In a head-to-head comparison, MRI was significantly more specific than CT, meaning it was better at correctly identifying tissue that was not diseased.³ Higher specificity translates directly into fewer false alarms, which means fewer unnecessary biopsies, fewer anxious weeks waiting for follow-up results, and lower downstream costs.

CT still has a clear advantage for the lungs. It picks up small pulmonary nodules that MRI almost entirely misses, which is why dedicated low-dose CT remains the recommended screening tool for lung cancer in high-risk groups like long-term smokers. If lung cancer screening is your primary concern, a whole-body MRI alone is not sufficient.

For everything else, including abdominal organs, the pelvis, soft tissues, and the musculoskeletal system, MRI provides equal or better characterization. The lack of radiation also makes it more suitable for repeat scanning. If you plan to screen annually or every few years, the cumulative radiation from repeated CT scans becomes a genuine consideration, whereas MRI can be repeated indefinitely without that concern.

What Screening Companies Do Not Always Tell You

The marketing from direct-to-consumer scanning companies tends to emphasize dramatic stories of early cancer detection while downplaying the much more common experience of finding benign abnormalities that require follow-up. A testimonial from someone whose scan caught a stage-one tumor is powerful, and those cases are real. But they represent a small minority of outcomes. For most people who walk through the door, the scan will either be clean or will turn up one or more incidental findings that are overwhelmingly likely to be benign but cannot be confirmed as such without additional testing.

Some companies also blur the line between screening and diagnosis. A screening scan can flag something suspicious, but it cannot definitively diagnose most conditions. If the scan finds a suspicious kidney mass, you will still need a dedicated renal MRI or a biopsy through your regular healthcare system. If it finds a thyroid nodule, you will need an ultrasound and possibly a fine-needle aspiration. These follow-up procedures are billed through your insurance or out of pocket, and they are where the real costs often pile up.

The industry is also young enough that long-term outcome data is thin. We know that whole-body MRI can detect cancers in asymptomatic people. What we do not yet know from rigorous trials is whether detecting those cancers through whole-body screening, as opposed to through conventional screening programs and symptom-driven workups, leads to better survival. It is plausible that it does, especially for cancers in organs not covered by standard screening. But “plausible” is different from “proven,” and that distinction is worth holding onto when evaluating a $2,500 purchase.

None of this means you should not get a scan. It means you should go in with realistic expectations about what the scan can and cannot do, a plan for how you will handle unexpected findings, and ideally a primary care physician who is willing to help you navigate whatever comes next.